Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BOLTthis companyBolt Biotherapeutics, Inc.	$6.35	-0.31×	0.39×	1.33×	-0.67×	-1476.7%	80.6%	-450.1%	-433.7%	-125.9%	-67.7%	-390.3%	0.87×	-0.35×	0×	3.59×	0.0%	2	-18.11	2	C
AEONAEON Biopharma, Inc.	$0.18	-0.28×	-0.2×	0×	-2.69×	-1320.4%	0.0%	0.0%	0.0%	71.3%	1180.0%	-158.6%	-0.65×	-2.02×	0×	0.49×	0.0%	2	-129.27	2	C
CINGCingulate Inc.	$4.40	-1.05×	9.4×	0×	-1.1×	-99.0%	0.0%	0.0%	0.0%	-894.8%	-176.5%	-73.8%	3.5×	0.11×	-21.57×	1.16×	0.0%	2	-3.41	2	C
CLRBCellectar Biosciences, Inc.	$1.31	-0.35×	0.78×	0×	0.24×	259.5%	0.0%	0.0%	0.0%	-219.7%	-222.5%	-300.5%	0.04×	0.59×	0×	2.96×	0.0%	2	-10.78	3	B
IMNNImunon, Inc.	$0.91	-0.56×	1.15×	0×	-0.02×	252.7%	0.0%	0.0%	0.0%	-205.3%	-181.5%	-175.3%	0.14×	0.56×	0×	2.32×	0.1%	1	-42.64	2	C+
INABIN8bio, Inc.	$0.96	-0.53×	0.37×	0×	0.83×	503.4%	0.0%	0.0%	0.0%	-70.5%	-65.5%	-124.2%	0.1×	1.44×	0×	8.82×	0.0%	2	-10.08	3	B-
Peer median	—	-0.53×	0.78×	0×	-0.02×	252.7%	0.0%	0.0%	0.0%	-205.3%	-176.5%	-158.6%	0.1×	0.56×	0×	2.32×	0.0%	2	-10.78	2	—